Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
Key Highlights
- ➤Jay R. Luly to retire as Enanta CEO by February 1, 2027, after 23 years
- ➤Tara L. Kieffer appointed Chief Operating Officer in newly created role
- ➤Board launches internal and external search for Luly’s successor
- ➤Luly will remain Strategic Advisor through 2027 to support leadership transition
Expert Statements
Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals
“After 43 years in the pharmaceutical and biotechnology industries, and 23 years as the Company’s CEO, I have decided that the time is right for me to begin my retirement from full-time executive leadership”
Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals
“I am enormously proud of what we have built together and of the talented team that has brought Enanta to this important stage in its development. I am particularly excited about the potential of our pipeline and the opportunity it represents for patients. The Company is well positioned for its next chapter, and I look forward to supporting a successful transition.”
Bruce L. A. Carter, Chairman of the Board of Enanta Pharmaceuticals
“During his distinguished tenure, Dr. Luly has provided exceptional leadership and made numerous important contributions, notably in helping bring forward cures for HCV infection, as well as potential treatments for RSV and immunologic diseases. We are grateful for his longstanding commitment and dedication, and we congratulate him on his well-deserved retirement.”
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the Company. Dr. Luly will continue to serve as a Strategic Advisor for the remainder of 2027 to support a smooth and orderly transition.
Get started
Create a free account to read the full story.